MACROGENICS, INC. Shareholders' Equity
MACROGENICS, INC. (MGNX) had Shareholders' Equity of $42.87 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent $42.87M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $21.20M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $55.59M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $67.00M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $42.87M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $21.20M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $55.59M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $67.00M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $46.62M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $79.12M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $116.06M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $120.07M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $57.82M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $106.15M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $152.61M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $193.98M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $171.54M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $109.27M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $142.01M 10-K · filed 2026-03-09 | |
| 2022-09-30 | $122.96M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $142.48M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $178.21M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $239.62M 10-K · filed 2025-03-20 | |
| 2021-09-30 | $291.44M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $319.05M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $350.53M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $295.88M 10-K · filed 2024-03-07 | |
| 2020-09-30 | $291.58M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $247.78M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $190.57M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $230.63M 10-K · filed 2023-03-15 | |
| 2019-09-30 | $255.20M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $294.45M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $320.62M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $242.88M 10-K · filed 2022-02-24 | |
| 2018-09-30 | $282.64M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $312.04M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $247.28M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $299.24M 10-K · filed 2021-02-25 | |
| 2017-09-30 | $189.47M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $231.35M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $234.64M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $268.75M 10-K · filed 2020-02-25 | |
| 2016-09-30 | $300.10M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $329.98M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $286.25M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $313.34M 10-K · filed 2019-02-26 | |
| 2015-09-30 | $339.33M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $211.69M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $230.99M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $121.29M 10-K · filed 2018-02-27 | |
| 2014-09-30 | $139.09M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $141.98M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $153.22M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $78.91M 10-K · filed 2017-02-28 | $78.91M 10-K · filed 2014-03-20 |
| 2013-09-30 | -$4.05M 10-Q · filed 2013-11-12 | |
| 2012-12-31 | -$8.24M 10-K · filed 2016-02-29 | -$8.24M 10-Q · filed 2013-11-12 |
| 2011-12-31 | -$17.48M 10-K · filed 2015-03-03 | -$17.48M 10-K · filed 2014-03-20 |
| 2010-12-31 | -$38.63M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |